BreezeBio
Biotech · Healthcare
BreezeBio Secures $60M Series B for Targeted Genetic Medicines
February 25, 2026$60M · Series B
BreezeBio, formerly GenEdit, raised $60 million in Series B funding led by Yuanta Investment and DSC Investment to advance its internal pipeline and NanoGalaxy delivery platform. The financing supports IND-enabling studies for lead candidate BRZ-101 in type 1 diabetes.
Lead Investors
Yuanta InvestmentDSC Investment
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.